Our Management Team


Dr Lim Su Wen, PhD

Founder and Chief Executive Officer
Genetically wired to be a combination of scientist and entrepreneur. Dr Lim has more than 12 years of research experience and 7 years of business management experience, specializing in the areas of oncology, cancer genetics and clinical diagnostics; trained in Malaysia, United Kingdom and Singapore. She is the founder of Oncode Scientific Sdn Bhd and the leading woman of their team.

Dr Lim got her Doctor of Philosophy (PhD) in Biosciences, specializing in cancer biology and drug discovery. She also has lots of experience in laboratory & business set-ups as well as research & development in molecular diagnostics. She believes that healthcare should be a basic right for all, not a privilege. With this thought in mind, she decided to bridge two ‘worlds’ together, linking up the academic and the clinical (frontline) ‘worlds’, gathering expertise across distinguished areas, aiming to develop diagnostic solutions that can really answer to the needs of patients & clinicians.

Dr Subramanian Yegappan, MBBS

Chief Medical Officer cum Pathologist
Dr Subramanian (Dr Mani) is a Pathologist with certifications from the American Board of Pathology in Anatomic & Clinical Pathology and Haematology and, from the American Board of Pathology & American Board of Medical Genetics in Molecular Genetic Pathology.

He worked as the Assistant Director, Laboratory for Molecular Diagnostics and as an Assistant Professor of Pathology, in the Department of Pathology, University of Texas Southwestern Medical Centre, Dallas, TX, USA from 2002-2004. Following that he set up, and has served as the Head, Laboratory for Clinical Haematology, Department of Haematology, Hospital Ampang since 2005. This is the national referral laboratory for Haematology in the Ministry of Health and performs diagnostic testing [including Targeted Resequencing by Next Generation Sequencing] on samples from patients with blood malignancies throughout the country.

Developments in Next Generation Sequencing combined with the availability of targeted therapies have revolutionised the diagnostic work-up of cancers. As sequencing of cancers becomes the standard of care, he wants to extend his expertise to solid tumours, and make these tests accessible to anyone with cancer in Malaysia.